These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 27272809)

  • 1. SOX2 and ALDH1 as Predictors of Operable Breast Cancer.
    Shima H; Kutomi G; Satomi F; Maeda H; Hirohashi Y; Hasegawa T; Mori M; Torigoe T; Takemasa I
    Anticancer Res; 2016 Jun; 36(6):2945-53. PubMed ID: 27272809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of ALDH1, CD44, OCT4 and SOX2 in tongue squamous cell carcinoma and their association with disease progression and prognosis.
    Huang CF; Xu XR; Wu TF; Sun ZJ; Zhang WF
    J Oral Pathol Med; 2014 Aug; 43(7):492-8. PubMed ID: 24450601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of the expression of ALDH1 and SOX2 in urothelial cancer of the upper urinary tract.
    Kitamura H; Torigoe T; Hirohashi Y; Asanuma H; Inoue R; Nishida S; Tanaka T; Fukuta F; Masumori N; Sato N; Tsukamoto T
    Mod Pathol; 2013 Jan; 26(1):117-24. PubMed ID: 22899292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of aldehyde dehydrogenase 1 and transcription factors in both primary breast cancer and axillary lymph node metastases as a prognostic factor.
    Ito M; Shien T; Omori M; Mizoo T; Iwamoto T; Nogami T; Motoki T; Taira N; Doihara H; Miyoshi S
    Breast Cancer; 2016 May; 23(3):437-44. PubMed ID: 25599843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of ALDH1 in axillary lymph node metastases is a prognostic factor of poor clinical outcome in breast cancer patients with 1-3 lymph node metastases.
    Nogami T; Shien T; Tanaka T; Nishiyama K; Mizoo T; Iwamto T; Ikeda H; Taira N; Doihara H; Miyoshi S
    Breast Cancer; 2014 Jan; 21(1):58-65. PubMed ID: 22407396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
    Miyoshi Y; Shien T; Ogiya A; Ishida N; Yamazaki K; Horii R; Horimoto Y; Masuda N; Yasojima H; Inao T; Osako T; Takahashi M; Tomioka N; Endo Y; Hosoda M; Doihara H; Miyoshi S; Yamashita H;
    Breast Cancer Res; 2016 Jul; 18(1):73. PubMed ID: 27368476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of CD44 and SOX2 expression is correlated with a poor prognosis in esophageal adenocarcinoma patients.
    Honing J; Pavlov KV; Meijer C; Smit JK; Boersma-van Ek W; Karrenbeld A; Burgerhof JG; Kruyt FA; Plukker JT
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S657-64. PubMed ID: 24833101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer.
    Ohi Y; Umekita Y; Yoshioka T; Souda M; Rai Y; Sagara Y; Sagara Y; Sagara Y; Tanimoto A
    Histopathology; 2011 Oct; 59(4):776-80. PubMed ID: 22014057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive in situ analysis of ALDH1 and SOX2 reveals increased expression of stem cell markers in high-grade serous carcinomas compared to low-grade serous carcinomas and atypical proliferative serous tumors.
    Fischer AK; Pham DL; Bösmüller H; Lengerke C; Wagner P; Bachmann C; Beschorner C; Perner S; Kommoss S; Fend F; Staebler A
    Virchows Arch; 2019 Oct; 475(4):479-488. PubMed ID: 31451895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression of aldehyde dehydrogenase 1 in invasive primary breast tumors and axillary lymph node metastases is associated with poor clinical prognosis.
    Dong Y; Bi LR; Xu N; Yang HM; Zhang HT; Ding Y; Shi AP; Fan ZM
    Pathol Res Pract; 2013 Sep; 209(9):555-61. PubMed ID: 23916993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
    Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
    Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node-positive breast cancers: a long-term follow-up study.
    Yoshioka T; Umekita Y; Ohi Y; Souda M; Sagara Y; Sagara Y; Sagara Y; Rai Y; Tanimoto A
    Histopathology; 2011 Mar; 58(4):608-16. PubMed ID: 21371077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALDH1 Expression and Vasculogenic Mimicry Are Positively Associated with Poor Prognosis in Patients with Breast Cancer.
    Xing P; Dong H; Liu Q; Zhao T; Yao F; Xu Y; Chen B; Zheng X; Wu Y; Jin F; Li J
    Cell Physiol Biochem; 2018; 49(3):961-970. PubMed ID: 30184527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression.
    Morimoto K; Kim SJ; Tanei T; Shimazu K; Tanji Y; Taguchi T; Tamaki Y; Terada N; Noguchi S
    Cancer Sci; 2009 Jun; 100(6):1062-8. PubMed ID: 19385968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of ALDH1 and SOX2 diffuse staining pattern of oral squamous cell carcinomas correlates to lymph node metastasis.
    Michifuri Y; Hirohashi Y; Torigoe T; Miyazaki A; Kobayashi J; Sasaki T; Fujino J; Asanuma H; Tamura Y; Nakamori K; Hasegawa T; Hiratsuka H; Sato N
    Pathol Int; 2012 Oct; 62(10):684-9. PubMed ID: 23005595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased SOX2 expression in less differentiated breast carcinomas and their lymph node metastases.
    Huang YH; Luo MH; Ni YB; Tsang JY; Chan SK; Lui PC; Yu AM; Tan PH; Tse GM
    Histopathology; 2014 Mar; 64(4):494-503. PubMed ID: 24382260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer.
    Kang EJ; Jung H; Woo OH; Park KH; Woo SU; Yang DS; Kim AR; Lee JB; Kim YH; Kim JS; Seo JH
    Neoplasma; 2014; 61(3):352-62. PubMed ID: 24824938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ALDH1 on prognosis and chemoresistance by breast cancer subtype.
    Kida K; Ishikawa T; Yamada A; Shimada K; Narui K; Sugae S; Shimizu D; Tanabe M; Sasaki T; Ichikawa Y; Endo I
    Breast Cancer Res Treat; 2016 Apr; 156(2):261-9. PubMed ID: 26975188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing Breast Cancer in a Population with Increased Prevalence of Triple-Negative Breast Cancer: Androgen Receptor and ALDH1 Expression in Ghanaian Women.
    Proctor E; Kidwell KM; Jiagge E; Bensenhaver J; Awuah B; Gyan K; Toy K; Oppong JK; Kyei I; Aitpillah F; Osei-Bonsu E; Adjei E; Ohene-Yeboah M; Brewer RN; Fondjo LA; Owusu-Afriyie O; Wicha M; Merajver S; Kleer C; Newman L
    Ann Surg Oncol; 2015 Nov; 22(12):3831-5. PubMed ID: 25743329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
    Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
    BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.